Results 161 to 170 of about 28,757,677 (326)

Truncated forms of human complement factor H [PDF]

, 1989
Marc Fontaine, M J Demares, Vesa Koistinen, Anthony J. Day, Christian Davrinche, Robert B. Sim, Jean Ripoche   +6 more
openalex   +1 more source

A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome.

Journal of the American Society of Nephrology, 2016
R. Challis, G. S. Araujo, E. Wong, Heather M. Anderson, A. Awan, A. Dorman, M. Waldron, V. Wilson, V. Brocklebank, L. Strain, B. Morgan, C. Harris, K. Marchbank, T. Goodship, D. Kavanagh   +14 more
semanticscholar   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Identification of a Kingella kingae factor H binding protein that is the major determinant of serum resistance. [PDF]

PLoS Pathog
Hernandez KA, Porsch EA, Muñoz VL, St Geme Iii JW.   +3 more
europepmc   +1 more source

4030) A Study of House Design System in Accordance with Social Mass-Demand : Part VI. Method of Indication of Various Factors in Accordance with H. Es.

, 1966
Hiroshi Kawasaki
openalex   +2 more sources

Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. [PDF]

, 1983
Michael K. Pangburn, Robert D. Schreiber, John S. Trombold, Hans J. Müller‐Eberhard   +3 more
openalex   +1 more source

Anti–Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases

Journal of Immunology, 2015
C. Blanc, C. Blanc, S. K. Togarsimalemath, S. Chauvet, S. Chauvet, M. L. Quintrec, B. Moulin, M. Büchler, T. Jokiranta, L. Roumenina, V. Frémeaux-Bacchi, M. Dragon-Durey   +11 more
semanticscholar   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Differential modulation of SARS-CoV-2 infection by complement factor H and properdin. [PDF]

Front Immunol
Kishore U, Varghese PM, Kumar C, Idicula-Thomas S, Mayora Neto M, Tsolaki AG, Ponnachan P, Masmoudi K, Al-Ramadi B, Vatish M, Madan T, Temperton N, Beirag N.   +12 more
europepmc   +1 more source